EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer

Seung-Hyuk Shim iD, Jung-Yun Lee iD, Yoo-Young Lee iD, Jeong-Yeol Park iD, Yong Jae Lee iD, Se Ik Kim iD, Gwan Hee Han iD, Eun Jung Yang iD, Joseph J Noh iD, Ga Won Yim iD, Joo-Hyuk Son iD, Nam Kyeong Kim iD und 8 weitere

Journal of Gynecologic Oncology · 2024

DOI: 10.3802/jgo.2024.35.e66 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2024. Verfasst von Seung-Hyuk Shim und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Endometrial Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the 2023 series, we summarized the major clinical research advances in gynecologic oncology based on communications at the conference of Asian Society of Gynecologic Oncology Review Course. The review consisted of 1) Endometrial cancer: immune checkpoint inhibitor, antibody drug conjugates (ADCs), selective inhibitor of nuclear export, CDK4/6 inhibitors WEE1 inhibitor, poly (ADP-ribose) polymerase (PARP) inhibitors. 2) Cervical cancer: surgery in low-risk early-stage cervical cancer, therapy for locally advanced stage and advanced, metastatic, or recurrent setting; and 3) Ovarian cancer: immunotherapy, triplet therapies using immune checkpoint inhibitors along with antiangiogenic agents and PARP inhibitors, and ADCs. In 2023, the field of endometrial cancer treatment witnessed a landmark year, marked by several practice-changing outcomes with immune checkpoint inhibitors and the reliable efficacy of PARP inhibitors and ADCs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsGenital Neoplasms, FemaleOvarian NeoplasmsEndometrial NeoplasmsFemaleHumansPoly(ADP-ribose) Polymerase InhibitorsImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

Antibodies, MonoclonalGynecologic NeoplasmsImmunoconjugatesImmunotherapyMolecular Targeted TherapyPoly(ADP-Ribose) Polymerase InhibitorSurvival

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Korea.
  • Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
  • Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Korea.
  • Department of Obstetrics and Gynecology, Inje University Sanggye Paik Hospital, Seoul, Korea.

ORCID-Profile: Seung-Hyuk Shim, Jung-Yun Lee, Yoo-Young Lee, Jeong-Yeol Park, Yong Jae Lee, Se Ik Kim, Gwan Hee Han, Eun Jung Yang, Joseph J Noh, Ga Won Yim, Joo-Hyuk Son, Nam Kyeong Kim, Tae-Hyun Kim, Tae-Wook Kong, Youn Jin Choi, Angela Cho, Hyunji Lim, Eun Bi Jang, Hyun Woong Cho, Dong Hoon Suh

Zitieren

APA

Shim, S. H., Lee, J. Y., Lee, Y. Y., Park, J. Y., Lee, Y. J., Kim, S. I., Han, G. H., Yang, E. J., Noh, J. J., Yim, G. W., Son, J. H., Kim, N. K., Kim, T. H., Kong, T. W., Choi, Y. J., Cho, A., Lim, H., Jang, E. B., Cho, H. W., & Suh, D. H. (2024). Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2024.35.e66

Vancouver

Shim SH, Lee JY, Lee YY, Park JY, Lee YJ, Kim SI, et al. Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer. Journal of Gynecologic Oncology. 2024. doi:10.3802/jgo.2024.35.e66

BibTeX
@article{Shim2024,
  author = {Shim, Seung-Hyuk and Lee, Jung-Yun and Lee, Yoo-Young and Park, Jeong-Yeol and Lee, Yong Jae and Kim, Se Ik and Han, Gwan Hee and Yang, Eun Jung and Noh, Joseph J and Yim, Ga Won and Son, Joo-Hyuk and Kim, Nam Kyeong and Kim, Tae-Hyun and Kong, Tae-Wook and Choi, Youn Jin and Cho, Angela and Lim, Hyunji and Jang, Eun Bi and Cho, Hyun Woong and Suh, Dong Hoon},
  title = {Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer},
  journal = {Journal of Gynecologic Oncology},
  year = {2024},
  doi = {10.3802/jgo.2024.35.e66}
}
Kostenlos starten →